Press Release

GigaOm Again Ranks IP Infusion as a Leader and Outperformer in its 2024 Network Operating System Radar Reports

For the fourth consecutive year, IP Infusion's OcNOS® is designated one of the most mature, complete, and field-tested disaggregated network operating systems available for a wide range of network environments in GigaOm's landscape analysis

SANTA CLARA, Calif., March 26, 2024 IP Infusion, the market leader in carrier-grade networking software systems, announced today that GigaOm has designated IP Infusion a Leader, Outperformer and Platform player for all three of its annual Network Operating System (NOS) Radar Reports. 

This is the fourth consecutive year that IP Infusion's OcNOS® platform has been deemed one of the most complete, mature and field-tested disaggregated platforms available of the 19 of the top NOS vendors GigaOm analysts evaluated. OcNOS again outperformed incumbent providers, including Cisco, Juniper and Arista. IP Infusion was ranked as a NOS Leader/Outperformer in NSPs and Mobile Network Operators (MNOs), Cloud and Network Service Providers (NSPs), and Enterprise and SMBs. 

IP Infusion was recognized as a Leader and Outperformer because of several strengths: its OcNOS allows for substantial cost savings, supports modern data center applications, delivers cloud-based network services, hosts virtual routing functions, and eases the transition from traditional networks. The reports also cited the steady momentum IP Infusion continues to build, including multiple announcements in 2023 detailing strong revenue growth, new product releases, and continued customer engagement across various verticals.

OcNOS Continues to Dominate As Top Network Disaggregation Solution 

GigaOm's continued rating of IP Infusion as a prominent performer is also supported by by IP Infusion's expanding customer base and other strengths, including:

  • 42,000 total OcNOS licenses sold and two million ports shipped globally
  • Nearly 130 PartnerInfusion partners, with 41 added in 2023
  • 100 new OcNOS customers added year-over-year

In addition, IP Infusion announced in January 2024 the launch of its innovative Network Automation Platform, IP Maestro, which brings the power of centralized management to the user via a web-based graphical user interface. Administrators can visualize network topologies and have direct access to network elements and device information through this interface, delivering point-and-click for OcNOS networking on white box hardware.

The award-winning OcNOS network operating system is the platform of choice for network operators looking for a flexible and feature-rich software alternative to mainstream and monolithic systems vendors. It brings both maturity and a proven record of diverse use cases for Aggregation Router (AGGR), Cell Site Router (CSR), Data Center (DC), Routed Optical Networking (RON) and more. 

"IP Infusion's continued leadership position in all our market sectors analysis is due to its innovative approach to meeting increased global demands for low-cost and reliable disaggregated solutions," said Ivan McPhee, GigaOm Analyst. "The network operating landscape is evolving rapidly, but IP Infusion's OcNOS continues to stand out as a proven, highly scalable, and quality open networking solution."

"It's a great honor to be recognized four years running by GigaOm as a Leader and Outperformer in its extensively researched Radar Reports," said Atsushi Ogata, President and CEO, IP Infusion. "We are committed to delivering flexible, disruptive solutions that help to mitigate supply chain challenges and further global connectivity. This recognition affirms IP Infusion's deep-seated expertise and dedication to providing solutions that are fully validated and tested for seamless interoperability." 

GigaOm is a leading global provider of technology industry trends; its researchers provide an objective overview of diverse markets and their underlying technology and help decision-makers grade solutions so they can make data-informed investment decisions. 

The GigaOm NOS Radar report noted that IP Infusion's OcNOS empowers enterprises to build scalable data center infrastructure, interconnect distributed IT resources, modernize existing networks, and substantially reduce costs, with the flexibility to support both legacy and next-generation use cases. Download a copy of the report, here.

IP Infusion 소개

IP Infusion manufactures open network software and solutions for carriers, service providers and data centers. With hundreds of customers and thousands of deployments, IP Infusion is a market leader in Network Operating Systems. Our flagship software platform OcNOS® allows network operators to disaggregate their networks, streamline operations, and reduce Total Cost of Ownership (TCO). Network OEMs may also disaggregate network devices to expedite time to market, offer comprehensive services, and achieve carrier-grade robustness.

IP Infusion is headquartered in Santa Clara, Calif., and is a wholly owned and independently operated subsidiary of ACCESS CO., LTD. Additional information can be found at http://www.IPInfusion.com.

IP Infusion and OcNOS are trademarks or registered trademarks of IP Infusion. ACCESS is a registered trademark or trademark of ACCESS CO., LTD. in the United States, Japan and/or other countries. All other trademarks, service marks, registered trademarks, or registered service marks mentioned are the property of their respective owners.

-end-

 

Media Contact:

Katherine Verducci

1903 PR

kverducci@1903pr.com

408.429.5779



IP Infusion 소개

IP Infusion은 오픈 네트워킹 소프트웨어의 선도적 공급업체로서, 서비스 프로바이더, 데이터센터, AI 패브릭 네트워크를 위한 캐리어급 네트워크 운영체제인 OcNOS를 제공합니다. 26+ 년의 네트워킹 전문성과 전 세계 600+ 오퍼레이터 실적을 바탕으로, Edgecore Networks, UfiSpace, Celestica 등 파트너의 검증된 오픈 하드웨어에서 개방적이고 멀티벤더이며 비용 효율적이고 유연한 네트워크 인프라를 구현합니다. IP Infusion은 ACCESS CO., LTD.(도쿄증권거래소: 4813)의 완전 자회사입니다.

미디어 문의

For press inquiries, analyst briefings, or media materials, please 팀에 문의 or email pr@ipinfusion.com.

미래예측 진술

본 보도자료에는 IP Infusion의 제품, 기술 및 계획에 관한 미래예측 진술이 포함될 수 있습니다. 미래예측 진술은 공개일 현재 이용 가능한 정보에 기초하며 위험과 불확실성을 수반합니다. 실제 결과는 다를 수 있습니다. 제품 계획, 기능, 출시 시기 및 제공 여부는 예고 없이 변경될 수 있으며 약정, 약속 또는 법적 의무를 구성하지 않습니다. IP Infusion은 미래예측 진술을 갱신할 의무를 지지 않습니다.